Tumor lysis syndrome: risk factors, diagnosis, and management

Pediatr Emerg Care. 2014 Aug;30(8):571-6; quiz 577-9. doi: 10.1097/PEC.0000000000000195.

Abstract

Tumor lysis syndrome (TLS) is a potentially fatal complication of induction therapy for several types of malignancies. Electrolyte derangements and even downstream complications may also occur prior to the initial presentation to a medical provider, before an oncologic diagnosis has been established. It is therefore imperative that emergency physicians be familiar with the risk factors for TLS in children as well as the criteria for diagnosis and the strategies for prevention and management. Careful evaluation of serum electrolytes, uric acid, and renal function must occur. Patients at risk for TLS and those who already exhibit laboratory or clinical evidence of TLS require close monitoring, aggressive hydration, and appropriate medical treatment.

Publication types

  • Case Reports

MeSH terms

  • Allopurinol / therapeutic use
  • Burkitt Lymphoma / diagnosis
  • Burkitt Lymphoma / drug therapy*
  • Child
  • Creatinine / blood
  • Electrolytes / blood
  • Fluid Therapy
  • Gout Suppressants / therapeutic use
  • Humans
  • Kidney / physiopathology
  • Male
  • Risk Assessment
  • Risk Factors
  • Tumor Lysis Syndrome / diagnosis
  • Tumor Lysis Syndrome / etiology*
  • Tumor Lysis Syndrome / physiopathology
  • Tumor Lysis Syndrome / therapy
  • Urate Oxidase / therapeutic use
  • Uric Acid / blood

Substances

  • Electrolytes
  • Gout Suppressants
  • rasburicase
  • Uric Acid
  • Allopurinol
  • Creatinine
  • Urate Oxidase